scholarly journals Canadian recommendations for the management of breakthrough cancer pain

2016 ◽  
Vol 23 (2) ◽  
pp. 96 ◽  
Author(s):  
P. Daeninck ◽  
B. Gagnon ◽  
R. Gallagher ◽  
J.D. Henderson ◽  
Y. Shir ◽  
...  
Keyword(s):  
Health Care ◽  
Cancer Pain ◽  
Health Care Providers ◽  
Immediate Release ◽  
Care Providers ◽  
Onset Of Action ◽  
Breakthrough Cancer Pain ◽  
Appropriate Treatment ◽  
Canadian Health ◽  
Canadian Health Care

Breakthrough cancer pain (btcp) represents an important element in the spectrum of cancer pain management. Because most btcp episodes peak in intensity within a few minutes, speed of medication onset is crucial for proper control. In Canada, several current provincial guidelines for the management of cancer pain include a brief discussion about the treatment of btcp; however, there are no uniform national recommendations for the management of btcp. That lack, accompanied by unequal access to pain medication across the country, contributes to both regional and provincial variability in the management of btcp.Currently, immediate-release oral opioids are the treatment of choice for btcp. This approach might not always offer optimal speed for onset of action and duration to match the rapid nature of an episode of btcp. Novel transmucosal fentanyl formulations might be more appropriate for some types of btcp, but limited access to such drugs hinders their use. In addition, the recognition of btcp and its proper assessment, which are crucial steps toward appropriate treatment selection, remain challenging for many health care professionals.To facilitate appropriate management of btcp, a group of prominent Canadian specialists in palliative care, oncology, and anesthesiology convened to develop a set of recommendations and suggestions to assist Canadian health care providers in the treatment of btcp and the alleviation of the suffering and discomfort experienced by adult cancer patients.

Intrauterine Contraception: Knowledge and Prescribing Practices of Canadian Health Care Providers

2019 ◽  
Vol 41 (8) ◽  
pp. 1084-1092 ◽  
Author(s):  
Jocelynn Cook ◽  
Ashley Waddington ◽  
Denise Black ◽  
Dustin Costescu ◽  
Danica Desjardins ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Care Providers ◽  
Prescribing Practices ◽  
Intrauterine Contraception ◽  
Canadian Health ◽  
Canadian Health Care

scholarly journals Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults

2010 ◽  
Vol 21 (4) ◽  
pp. 159-172 ◽  
Author(s):  
Anita Rachlis ◽  
Marianne Harris ◽  
Richard Lalonde ◽  
Stephen D Shafran ◽  
Cécile Tremblay ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Hiv Treatment ◽  
Care Providers ◽  
Expert Opinions ◽  
Hiv Management ◽  
Conference Presentations ◽  
Canadian Health ◽  
Canadian Health Care ◽  
Group Members

BACKGROUND AND OBJECTIVES: A Canadian group, consisting of six physicians and an HIV researcher with significant experience and knowledge in HIV management, reviewed the available data and developed guidelines for Canadian health care providers (who treat HIV infection) on the appropriate use of maraviroc (UK-427,857) in HIV-infected adults.METHODS: Evidence from the published literature and conference presentations, as well as the expert opinions of the group members were considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from four other physicians across Canada with expertise in HIV treatment and experience with the use of maraviroc. The final recommendations represent the core group’s consensus agreement once all feedback was considered.RESULTS/CONCLUSIONS: Recommendations were developed to guide physicians and other health care providers in the optimal use of maraviroc. The recommendations were considered in light of the fact that the decision to include maraviroc in an antiretroviral regimen depends not only on issues that concern all antiretroviral agents, such as efficacy, safety, resistance and drug interactions, but also on the issue of viral tropism, which is unique to maraviroc and other CCR5 inhibitors.

scholarly journals The Safe Resumption of Elective Plastic Surgery in Accredited Ambulatory Surgery Facilities During the COVID-19 Pandemic

2020 ◽  
Author(s):  
Mitchell Brown ◽  
Stephanie Eardley ◽  
Jamil Ahmad ◽  
Frank Lista ◽  
Scott Barr ◽  
...  
Keyword(s):  
Health Care ◽  
Plastic Surgery ◽  
Health Care System ◽  
Health Care Providers ◽  
Care Providers ◽  
Canadian Health Care System ◽  
Canadian Health ◽  
Canadian Health Care ◽  
The Impact ◽  
Care System

Abstract Background On March 11, 2020 the World Health Organization declared COVID-19 a worldwide pandemic resulting in an unprecedented shift in the Canadian health care system, where protection of an already overloaded health care system became a priority; all elective surgeries and non-essential activities were ceased. With the impact being less than predicted, on May 26, 2020, elective surgeries and non-essential activities were permitted to resume. Objectives To examine outcomes following elective aesthetic surgery and the impact on the Canadian health care system with the resumption of these services during the COVID-19 worldwide pandemic. Methods Data was collected in a prospective manner on consecutive patients undergoing elective plastic surgery procedures in six accredited ambulatory surgery facilities. Data included patient demographics, procedural characteristics, COVID-19 PCR test status, airway management and postoperative outcomes. Results 368 patients underwent elective surgical procedures requiring a general anesthetic. All 368 patients that underwent surgery were negative on pre visit screening. A COVID-19 PCR test was completed by 352 patients (95.7%) and all were negative. In the postoperative period, seven patients (1.9%) had complications, three patients (0.8%) required a hospital visit, and one patient (0.3%) required hospital admission. No patients or health care providers developed COVID-19 symptoms or had a positive test for COVID-19 within 30 days of surgery. Conclusions With appropriate screening and safety precautions, elective aesthetic plastic surgery can be performed in a manner that is safe for patients and health care providers and with a very low risk for accelerating virus transmission within the community.

Sign in / Sign up

Export Citation Format

Share Document